College Station, Texas – February 5th, 2024 Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) of cell and gene therapies (CGTs), today announced the appointment of Paul Kim as chief executive officer (CEO). 

As incoming CEO, Kim will manage daily operations and provide strategic direction to Matica Bio as it rapidly expands both its capacity and capability in the U.S. and Korea. Yun Jeong Song, outgoing president and CEO, will take her new role as a president of Matica Holdings.

Kim brings to Matica Bio nearly three decades of experience across CDMO, CRO and R&D Biopharma sectors as CEO, Managing Director, Chief Business Officer, Managing Partner and Executive Board at WCCT Global, Genopis, Cobra Biologics, Cognate BioServices, and Novartis Venture Fund.  Kim led first global biotech fund focusing on innovative Asian biotech investments at Novartis Venture Fund.  Kim is also the founder of Forward Equity Partners (Formerly Medivate Partners), a private equity firm focused on cross-border healthcare and life sciences investments – first ever in Korea.  Specializing in gene and cell therapy, he has invested in over 15 global biotechs and 4 CDMOs over last 10 years.  He currently serves on the Boards of SCAI Therapeutics, and Riva Therapeutics in San Diego.   Kim earned his bachelor’s degree in molecular cell biology from University of California, Berkeley.

Kim will oversee cell and gene therapy (CGT) manufacturing operations, processes, operations, and business strategy as CEO during period of rapid expansion across US and Korea.

“Matica Bio’s bespoke approach to CGT manufacturing at its purpose-built GMP facility is perfectly suited to successfully manufacture cell and gene therapies, unlike any other in the CDMO industry today,” said Kim. “Together with deep scientific expertise in-house, I look forward to propelling Matica Bio forward in rapidly changing CGT industry.”

Kim’s appointment as CEO of Matica Bio is the latest in a series of strategic milestones that the company has announced.  Along with Kim’s appointment, Matica Bio plans to further expand Board capacity later this year. Last year, the company also optimized several critical components for efficient CGT manufacturing process, including its fully closed system approach, 100% single-use platform, advanced analytical capabilities and launch of its high performance proprietary cell line, MatiMaxTM.

About Matica Biotechnology, Inc.
Matica Biotechnology, Inc. (Matica Bio) is a CDMO specializing in fully integrated cell and gene therapy manufacturing. The industry-leading experts at our state-of-the-art facility in Texas, deliver breakthrough therapies rapidly and safely through innovative manufacturing solutions. To learn more about Matica Bio, Please visit

Media Contact
Emily Stearney, HDMZ